3 Top Canadian Pharma Stocks for Ambitious Investors

Pharma stocks like Zymeworks Inc. (TSX:ZYME)(NYSE:ZYME) are coming into their own, offering growth investors a lot of upside potential.

| More on:
Test tubes

Image source: Getty Images

Specialty drug companies offering a lot of upside are finding favour with growth investors, but how high can these stocks climb, and are they good value for money? Let’s take a look at three of the most exciting pharma stocks on the TSX and see how they’re performing.

Aurinia Pharmaceuticals

A biopharmaceutical company with a bright future, Aurinia (TSX:AUP)(NASDAQ:AUPH) has long been talked up by pundits as a focal point for growth investors looking for niche medical exposure. Aurinia is in the business of trialing a novel drug called voclosporin, an immune system suppressant with a number of uses from dry eye to kidney inflammation. With its second-quarter report due out tomorrow, it’s worth reviewing the stock’s stats ahead of a potential investment.

A possibly gravity-defying share price marks Aurinia out as a clear target for serious growth investors. Its one-year returns of 21.5% compares favourably with the Canadian biotech industry average of 4.6%, while looking further back, five-year returns of 93.8% are suitably high, especially when one considers that the industry has returned only 14.3% for the same half-decade.

Viemed Healthcare

With one-year returns of 127.3%, Viemed (TSX:VMD) is one of the top-performance pharma stocks to get invested in if a quick turnaround is your goal when it comes to capital gains. While it hasn’t got the stolid balance sheet or exciting future outlook of Aurinia, for a short-term play designed to bring in quick cash, Viemed should be on a momentum investor’s wish list.

A high-octane specialty pharma stock with some key quality indicators, Viemed is a developer of novel treatments for sufferers of breathing-related complaints, such as chronic respiratory conditions and sleep apnea and patients being treated for neuromuscular conditions. High returns in a niche market are the name of the game in biopharma investing, and Viemed ticks all the boxes.

Zymeworks

Zymeworks (TSX:ZYME)(NYSE:ZYME) is a good play for value, with a price-to-book that undercuts the average for a biotech stock. A mixed Q2 just saw Zymeworks’s EPS miss by a hair’s breadth, though its revenue beat is certainly encouraging, especially if investors are holding for the long term. Perhaps even more encouraging, though, is Zymeworks’s deal-making strategy: The cancer treatment company has buddied up with eight major pharma businesses.

Promising lab data could see Zymework’s best hope, a drug called ZW25, add serious upside to the company’s share price in coming years. In the meantime, a collaboration with another business in the cancer treatment space, BeiGene, will help open territories in Oceania and Asia. A sturdy balance sheet and industry-normal value make the stock a low-stress play for upside in the biopharma space.

The bottom line

The three stocks listed here are diverse enough to be held concurrently in a single capital gains portfolio, though a low-risk investor may not want to put too many of their eggs in the same basket. For long-term upside, Aurinia could be the best bet here with its mix of upward momentum and reasonable value, though Viemed and Zymeworks also display steep upside potential.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Victoria Hetherington has no position in any of the stocks mentioned. The Motley Fool owns shares of Viemed Healthcare Inc. Viemed is a recommendation of Hidden Gems Canada.

More on Stocks for Beginners

analyze data
Stocks for Beginners

How to Start Investing With Little Money

ETFs are a great way for beginner investors to start building a portfolio with little capital.

Read more »

A stock price graph showing growth over time
Stocks for Beginners

3 Undervalued Stocks to Triple Your Portfolio

These three undervalued stocks are the perfect choice for those looking for stable but strong growth in the next few…

Read more »

clock time
Stocks for Beginners

Brookfield Asset Management (TSX:BAM.A) Stock Is Down 20%: Time to Buy?

Brookfield Asset Management (TSX:BAM.A) has fallen 20% this year. Is now the time to pick up this top Canadian stock?

Read more »

money cash dividends
Dividend Stocks

Canadian Investors: Where to Put $100 Right Now

Canadians with $100 to invest can put their money to work in three low-priced, dividend-paying TSX stocks.

Read more »

Dice engraved with the words buy and sell
Dividend Stocks

Not Every Cheap Stock has Value: 1 Stock to Buy, 1 to Sell, and 1 to Hold

The market downturn has created an opportunity to buy value stocks at a bargain. Here’s a guide to optimizing your…

Read more »

Credit card, online shopping, retail
Stocks for Beginners

Need Cash? Get a New Credit Card

Canadians can create some savings by simply finding a new credit card that offers more perks and bonuses, and use…

Read more »

stock data
Stocks for Beginners

New to Investing? Here’s Why Dividend Stocks Are the Best to Buy Now

As the economy continues to worsen and interest rates move higher, here's why these two dividend stocks are some of…

Read more »

value for money
Stocks for Beginners

3 TSX Stocks That Are Fantastic Deals Right Now

Bear markets are the perfect time for long-term TSX investors to load up on high-quality stocks at bargain prices. Here…

Read more »